We began with the master regulator of the UPR, GRP78 (HSPA5), the expression of which correlates with poorer survival of GBM patients (Supplementary Fig. 2) and was previously reported to confer chemoresistance in glioma cells13. The gene discussed is HSPA5; the disease is central nervous system cancer.